The plasma concentrations of melatonin in man, fasting and fed, were determined after ingestion of three different oral preparations. A dose of 2 mg was given as either a gelatine capsule, a solution in corn oil or as a slow-release pill. Gelatine capsules and the corn oil preparation gave reproducibly timed peak plasma concentrations, 30 to 60 min after ingestion regardless of nutritional status, and plasma melatonin remained at or above endogenous night-time levels for 3-4 h with mean elimination half-lives of 0.54 to 0.67 h. The slow-release preparation usefully extended high plasma melatonin concentrations for 5-7 h after ingestion but the timing of peak concentrations was very dependent on nutritional status. These preparations should be of use in the study of timed melatonin administration in man.
Introduction
The pineal neurohormone melatonin in physiological quantities is known to have potent effects on reproductive (Reiter, 1980; Bittman, et al., 1983) and other functions (Hoffman, 1981) in photoperiodic seasonal breeders. Its effectiveness is highly dependent on the time of its administration (Tamarkin, et al., 1976) and the duration of high plasma concentrations (Carter & Goldman, 1983; Arendt et al., 1983 ). It appears to act in a manner analogous to that of the light-dark cycle.
In rodents pharmacological doses of melatonin will entrain the rest-activity cycle (Redman et al., 1983) thus acting on the circadian system as a time-cue or zeitgeber. In pharmacological quantities it is known to have hypnotic properties in man and other species (Cramer et al., 1974) and to have very low toxicity (Sugden, 1980; Lerner & Nordlund, 1978) . So far, however, no other consistent observation of possible therapeutic benefit has emerged. An agent such as melatonin capable of entraining, or speeding up the resynchronisation (Murakami et al., 1983) taken with a little water (approx 50 ml). Blood samples were taken from an indwelling venous cannula into heparinised tubes at 0.25, 0.5, 0.75, 1,2,3,4,5,6 and 7 h after dosing, and immediately centrifuged. Plasma was separated and stored at -20°C until analysed for melatonin by radio-immunoassay using the method of Fraser et al. (1982) . The interassay coefficients of variation for four quality control samples during this study were 8% (25 pg/ml), 7.1% (108 pg/ml), 12% (141 pg/ ml) and 4.9% (526 pg/ml) and the limit of detection was 10 pg/ml.
Analysis of results
Areas under the plasma concentration curve (AUC), calculated to the limit of detectability above basal melatonin concentrations were derived using a computer programme, 'Stripe' (Johnston & Woollard, 1982) , as were the timing of peak plasma melatonin (tmax) and the elimination half-life. Basal melatonin concentrations (at 10.00 h) were subtracted from postingestion plasma concentrations prior to analysis. Figure 2 . Clearly, when subjects had eaten, high plasma concentrations of melatonin were maintained for 5-7 h in four out of five individuals with values above the physiological daytime range (< 10-23 pg/ml in this study) and within or above the night-time range (< 10-250 pg/ml, as observed in our laboratory). Secondary peaks were evident in the majority of individuals and were particularly marked in the fasted state. Comparison of areas under the curve indicated that no significant differences were present between fasting and fed plasma profiles. The peak plasma concentrations obtained with this preparation were considerably lower than those given by the gelatine and corn oil preparations (Figures 1  and 2 ) and the timing of peak concentrations was inconsistent particularly in the fasting state.
Discussion
Very few human studies of the plasma pharmacokinetics of melatonin have been undertaken. Wetterberg (1978) (Fraser et al., 1983) and thus any hangover effect from previous treatment is very unlikely.
The slow-release preparation is of interest in that it is able to maintain high, near physiological, plasma levels in most individuals for 5-7 h. Unfortuantely, the nutritional state of the individual greatly influences the timing of peak concentrations and the pattern of release into the blood.
Any investigation of the physiological functions of melatonin in man will require it to be administered in as near a physiological manner as possible. Thus, with careful control of nutritional status the slow-release preparation is likely to be useful. On the other hand, the reproducible timing of high blood concentrations achieved by both corn oil and gelatine capsule preparations, independent of nutritional status, provides a pharmacological tool for investigating the effects of timed melatonin administration in man.
This work was supported by the South West Thames Regional Health Authority and the M.R.C.
